Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs - Wikidata - wikimedia - TriplyDB

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

http://www.wikidata.org/entity/Q28186050

about

sameAs

Use of NSAIDs in treating patients with arthritis Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview Diclofenac with or without an antiemetic for acute migraine headaches in adults Diclofenac with or without an antiemetic for acute migraine headaches in adults Diclofenac with or without an antiemetic for acute migraine headaches in adults TNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activation Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway Aspirin, cyclooxygenase inhibition and colorectal cancer Identification of a human NF-kappaB-activating protein, TAB3 Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk New insights into the use of currently available non-steroidal anti-inflammatory drugs A systematic review of aspirin in primary prevention: is it time for a new approach?Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives Natural Products for Antithrombosis Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways Genetic and pharmacological analysis of prostanoid receptor function Novel determinants of plaque instability Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages Protein kinase Cepsilon is required for macrophage activation and defense against bacterial infection Clinical Pharmacology and Cardiovascular Safety of Naproxen Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: cohort study based on prospective data Network meta-analysis of migraine disorder treatment by NSAIDs and triptans.Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity.Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse Tyrosine phosphorylation is required for IkappaB kinase-beta (IKKbeta) activation and function in osteoclastogenesis Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinoma Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding.Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.Clinical pharmacology of etoricoxib.Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding.Low-dose SoluMatrix diclofenac : a review of safety across two Phase III studies in patients with acute and osteoarthritis pain.Molecular-based therapeutic approaches in treatment of anorexia of aging and cancer cachexia.Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.Pharmacological and dietary prevention for colorectal cancer.Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines.Antidepressant compounds can be both pro- and anti-inflammatory in human hippocampal cells.

P2860

Q21195252-C7EDBCD7-DE13-48C9-B520-953BE30C0EB6 Q22306433-415B6983-BA7C-43EA-82BC-42225AB2456D Q24197666-C774569E-0380-4ADE-A810-0D82B850169A Q24203701-344181D2-3C61-42DA-BEE4-6E6BC5260C67 Q24234848-11EF1282-92F8-4287-A853-DCBF277B08DA Q24297399-A131262E-BDE7-4BBA-93EC-C93F62D8B110 Q24306909-0B0C33D6-CDCE-4EDA-A83D-C7E880627BE8 Q24598813-1F7A2617-6FD1-4E42-A2F9-C59DB01073A7 Q24621651-45DBEE06-98EA-4A0E-A95D-BC54D0A4238D Q26778352-7325D922-AEA8-4A6B-A88A-A1257BEE7611 Q26852330-01ABAB12-2F37-4714-9ECE-FA6DD246EF2C Q26864015-D54A0E7A-8D82-4447-9140-2334A164613E Q27012539-528E10EE-9C88-4606-B8EF-4E73C87EDD3A Q28084934-6F2C7206-201B-4702-9A2E-D3024C479613 Q28168258-AB157435-DB18-40BC-83A2-350C11F597A6 Q28185341-77847E4E-C65B-41A7-A1DF-A0AFA5A3E76B Q28186062-9D700E8C-1A1B-4077-8FB3-2181B5AFADD1 Q28187632-2C08E831-59D7-493E-9D1D-1402B2D74063 Q28193777-DEF332ED-C5E2-41FE-ABC5-E9468FB366EB Q28217885-C9CA7D69-EF49-48C2-BE0F-182F5A4460B4 Q28594768-1E6C87B7-826A-497B-862E-CBCA8CA93991 Q30360728-369BF096-6398-4088-BDBC-02FE85FAE7E8 Q30570853-15F283C6-A910-4786-B89C-88C6B130B72B Q30831647-1BBB533C-BCE2-4C1F-A00F-0C7E9830A236 Q33849756-BFA92D18-02A2-4482-9255-32FB77CDC98F Q33918377-88112F1F-4E17-492F-AE74-C3DCC4A6E209 Q34055858-1B260BFB-D77B-489B-B5C2-33C97E31C375 Q34430932-A34772FB-5EE2-4608-AEA3-41C8C51B7AFE Q34475981-EBC87DD3-240D-4F1F-A002-59AD624D3131 Q34499168-86707D1C-3A0E-4CBB-B702-5C1A7746CF71 Q34530950-439B6307-C0E6-4483-9296-357ACEE8B5A8 Q34570225-37318F43-F6E4-4CE3-B3CB-4DD9AA6B6F55 Q34617038-3B674046-78D5-4F46-8904-2AACB3AC162A Q34669949-6179C642-622B-4AFA-ADCE-23BF26AD2838 Q34764949-84F73F44-6C91-44B3-95FD-4EF6E5A7D11A Q35048654-03D1F615-78D9-46C5-954C-5DC192744601 Q35051366-7D4596EA-DF74-4A98-9FFF-479049631B77 Q35083808-BE902502-98B0-4A9F-96DB-62A29A121A69 Q35161476-196E0E65-B759-4421-BD3C-6EDE91ACB9BC Q35179051-D9CEB992-9429-4E14-8DEB-A7A7D362D554

P2860

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

http://www.wikidata.org/entity/Q28186050

description

2001 nî lūn-bûn

@nan

2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@ast

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@en

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@nl

type

label

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@ast

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@en

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@nl

prefLabel

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@ast

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@en

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@nl

P1433

Q28186050-CCD1BEE0-8D44-4855-A659-895EA887DCF5

P1476

Q28186050-ACEEC656-4716-4FCE-9B51-6167F7F397D7

P2093

Q28186050-4AC86939-80BC-486E-B136-67DCEC7EA659

Q28186050-9CFE33F3-2DAF-4799-BF3D-25049091AEEF

Q28186050-F86CAC40-92B0-4F35-AD84-D70B325358FE

P2860

Q28186050-08158B39-BCD4-4204-8113-5A0230DF096A

Q28186050-1BE4DBC1-FB99-4030-A12D-304081D96354

Q28186050-2B728DF5-7E25-4489-9524-F25AC5C51239

Q28186050-4045BD69-7A34-4627-85F6-05FF3AE4B617

Q28186050-44399488-2FC8-4E71-9830-88C54B3111F0

Q28186050-6FEFDC3A-1B76-4108-9EB8-E015C3DEE574

Q28186050-77F672FB-BDBE-4CDB-A90A-F23E8A1AB320

Q28186050-79D26F8E-8301-464C-866C-A2513A6BC35D

Q28186050-80DA1F93-4981-4951-97E9-7F0EC68DBF04

Q28186050-82618654-1A51-4BE2-90F7-36C6657463C2

P304

Q28186050-DE765959-E8F2-4BCC-8572-1971DC5F8F56

P31

Q28186050-C61EFA26-3A9C-481B-A622-547A451B146B

P3181

Q28186050-AA213AF2-2F2F-4B04-92DC-A66962B21898

P356

Q28186050-3C40BAA3-4392-4B36-83F1-B6F72FCF5B92

Q28186050-A0AE2AC9-95B8-416F-888F-E948C64B390B

P407

Q28186050-317F0408-7336-44A2-BF65-D72F33949CCF

P433

Q28186050-DE40ABD3-B8C4-47F2-9E9D-A291D712C2CF

P478

Q28186050-748B71B7-6446-4DF2-B749-3F0C4F42B53F

P577

Q28186050-E615B59C-ED66-47A4-BD17-C6E330AFBFC5

P5875

Q28186050-6400AFCA-8B1E-4059-AE74-6681CAEE8D76

P698

Q28186050-753B9156-624F-45CB-83B8-57C03F78F245

P932

Q28186050-A45255DC-5ACC-4734-8CCE-E660BBA6569E

P3181

P356

P1433

Journal of Clinical Investigation

P1476

Cyclooxygenase-selective inhib ...... tivity into clinical read-outs

@en

P2093

C Patrono

http://www.w3.org/2001/XMLSchema#string

L A García Rodríguez

http://www.w3.org/2001/XMLSchema#string

P Patrignani

http://www.w3.org/2001/XMLSchema#string

P2860

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

Regulated formation of eicosanoids

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man

Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice

Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

Cyclooxygenase-2 and carcinogenesis.

P304

7-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4620770

http://www.w3.org/2001/XMLSchema#string

P356

10.1172/JCI13418

http://www.w3.org/2001/XMLSchema#string

10.1172/JCI200113418

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11906386

http://www.w3.org/2001/XMLSchema#string

P698

11435450

http://www.w3.org/2001/XMLSchema#string

P932

209347

http://www.w3.org/2001/XMLSchema#string